Abstract
Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Current Respiratory Medicine Reviews
Title: New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III
Volume: 3 Issue: 2
Author(s): Marcus B. Conde and Margarita Elsa Villarino
Affiliation:
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Abstract: Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Export Options
About this article
Cite this article as:
Conde B. Marcus and Elsa Villarino Margarita, New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III, Current Respiratory Medicine Reviews 2007; 3(2) . https://dx.doi.org/10.2174/157339807780599144
DOI https://dx.doi.org/10.2174/157339807780599144 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Benefits of Structural Genomics for Drug Discovery Research
Infectious Disorders - Drug Targets α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]
Current Medicinal Chemistry In Vitro and In Vivo Models of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Molecular Biomarkers of Disease for Diagnosis and Drug Development
Current Medicinal Chemistry Antiretroviral Therapy in Prevention of HIV and TB: Update on Current Research Efforts
Current HIV Research MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Copper(0) Catalyzed C-N Coupling Approach for the Synthesis of Thiourea Linked Quinoline Analogues Using Aqueous Media: Rationale and Biological Study
Letters in Organic Chemistry Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science CRISPeering: Bioengineering the Host Cells through CRISPRCas9 Genome Editing System as the Next-generation of Cell Factories
Recent Patents on Biotechnology Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Relationship of Azole Resistance with the Structural Alteration of the Target Sites: Novel Synthetic Compounds for Better Antifungal Activities
The Natural Products Journal Synthesis, In vitro and In silico Studies of Benzothiazole Azo-Ester Derivatives as Anti-TB Agents
Anti-Infective Agents Virtual Screening Techniques and Current Computational Infrastructures
Current Pharmaceutical Design β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry HIV-1 Infection In Children: A Clinical and Immunologic Overview
Current HIV Research 3D Cell and Scaffold Patterning Strategies in Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis
Current Pharmaceutical Design Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine